.png){kind=small}
[Skypost] Early Detection of Alzheimer’s disease: The Promise of Blood-Based p-tau Testing
- Codex
- 4 days ago
- 1 min read
Alzheimer’s disease (AD) is a progressive neurodegenerative disorder that affects memory, cognition, and daily functioning. In Hong Kong, it accounts for 65% of all dementia cases and ranks as the 8th leading cause of death. While the disease is currently irreversible, early detection and intervention can significantly slow its progression and improve quality of life.
The Breakthrough: p-tau 217 Blood Test
Recent medical advances have introduced a new blood test that detects phosphorylated tau protein (p-tau 217)—a key biomarker of Alzheimer’s. This test can identify potential AD patients up to 20 years before symptoms appear, with an accuracy rate of 90%. It works by detecting abnormal tau and amyloid-beta protein accumulation in the brain, which are hallmarks of the disease.
Why Early Diagnosis Matters
Early detection allows patients to benefit from anti-amyloid therapies, which have shown promising results. Studies reveal that patients with mild symptoms who undergo treatment for 18 months experience:
51% improvement in cognitive function
27% slower decline in daily living abilities
These therapies help clear brain plaques and preserve independence, reducing the burden on caregivers.
🏥 Local Support & Screening Programs
Hospitals like Canossa Hospital now offer subsidized screening programs, including the p-tau blood test and cognitive assessments like the Montreal Cognitive Assessment (MoCA). These initiatives aim to identify high-risk individuals early and guide them toward timely treatment.
Comments